Natalizumab therapy of multiple sclerosis: recommendations of the Multiple Sclerosis Study Group—Italian Neurological Society (Q59389216)

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21234775%20AND%20SRC:MED&resulttype=core&format=json

20 January 2020

title

Natalizumab therapy of multiple sclerosis: recommendations of the Multiple Sclerosis Study Group--Italian Neurological Society (English)

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21234775%20AND%20SRC:MED&resulttype=core&format=json

20 January 2020

0 references

Maria Giovanna Marrosu

3

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21234775%20AND%20SRC:MED&resulttype=core&format=json

20 January 2020

Antonio Bertolotto

6

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21234775%20AND%20SRC:MED&resulttype=core&format=json

20 January 2020

Maria Trojano

7

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21234775%20AND%20SRC:MED&resulttype=core&format=json

20 January 2020

Paolo Gallo

8

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21234775%20AND%20SRC:MED&resulttype=core&format=json

20 January 2020

Diego Centonze

10

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21234775%20AND%20SRC:MED&resulttype=core&format=json

20 January 2020

Enrico Millefiorini

11

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21234775%20AND%20SRC:MED&resulttype=core&format=json

20 January 2020

Vincenzo Brescia Morra

13

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21234775%20AND%20SRC:MED&resulttype=core&format=json

20 January 2020

Maria Pia Amato

14

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21234775%20AND%20SRC:MED&resulttype=core&format=json

20 January 2020

Alessandra Lugaresi

15

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21234775%20AND%20SRC:MED&resulttype=core&format=json

20 January 2020

Gianluigi Mancardi

16

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21234775%20AND%20SRC:MED&resulttype=core&format=json

20 January 2020

1

A Ghezzi

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21234775%20AND%20SRC:MED&resulttype=core&format=json

20 January 2020

25

G Savettieri

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21234775%20AND%20SRC:MED&resulttype=core&format=json

20 January 2020

author name string

L M E Grimaldi

2

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21234775%20AND%20SRC:MED&resulttype=core&format=json

20 January 2020

C Pozzilli

4

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21234775%20AND%20SRC:MED&resulttype=core&format=json

20 January 2020

G Comi

5

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21234775%20AND%20SRC:MED&resulttype=core&format=json

20 January 2020

R Capra

9

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21234775%20AND%20SRC:MED&resulttype=core&format=json

20 January 2020

S Sotgiu

12

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21234775%20AND%20SRC:MED&resulttype=core&format=json

20 January 2020

D Caputo

17

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21234775%20AND%20SRC:MED&resulttype=core&format=json

20 January 2020

E Montanari

18

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21234775%20AND%20SRC:MED&resulttype=core&format=json

20 January 2020

L Provinciali

19

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21234775%20AND%20SRC:MED&resulttype=core&format=json

20 January 2020

L Durelli

20

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21234775%20AND%20SRC:MED&resulttype=core&format=json

20 January 2020

R Bergamaschi

21

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21234775%20AND%20SRC:MED&resulttype=core&format=json

20 January 2020

P Bellantonio

22

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21234775%20AND%20SRC:MED&resulttype=core&format=json

20 January 2020

M R Tola

23

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21234775%20AND%20SRC:MED&resulttype=core&format=json

20 January 2020

S Cottone

24

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21234775%20AND%20SRC:MED&resulttype=core&format=json

20 January 2020

G Tedeschi

26

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21234775%20AND%20SRC:MED&resulttype=core&format=json

20 January 2020

MS-SIN Study Group

27

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21234775%20AND%20SRC:MED&resulttype=core&format=json

20 January 2020

publication date

1 April 2011

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21234775%20AND%20SRC:MED&resulttype=core&format=json

20 January 2020

published in

Neurological Sciences

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21234775%20AND%20SRC:MED&resulttype=core&format=json

20 January 2020

volume

32

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21234775%20AND%20SRC:MED&resulttype=core&format=json

20 January 2020

issue

2

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21234775%20AND%20SRC:MED&resulttype=core&format=json

20 January 2020

page(s)

351-358

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21234775%20AND%20SRC:MED&resulttype=core&format=json

https://scigraph.springernature.com/pub.10.1007/s10072-010-0469-0

20 January 2020

exact match

0 references

cites work

Progressive multifocal leukoencephalopathy after natalizumab therapy for Crohn's disease

1 reference

12 December 2020

Natalizumab treatment for multiple sclerosis: recommendations for patient selection and monitoring

1 reference

12 December 2020

Natalizumab induces a rapid improvement of disability status and ambulation after failure of previous therapy in relapsing-remitting multiple sclerosis.

1 reference

12 December 2020

Natalizumab plus interferon beta-1a for relapsing multiple sclerosis

1 reference

12 December 2020

Neurologic consequences of the immune reconstitution inflammatory syndrome (IRIS).

1 reference

12 December 2020

Natalizumab-associated progressive multifocal leukoencephalopathy in patients with multiple sclerosis: lessons from 28 cases

1 reference

12 December 2020

Natalizumab drug holiday in multiple sclerosis: poorly tolerated

1 reference

12 December 2020

The use of immunosuppressive agents in the treatment of multiple sclerosis: a critical review

1 reference

12 December 2020

Evaluation of patients treated with natalizumab for progressive multifocal leukoencephalopathy

1 reference

12 December 2020

Immunologic, clinical, and radiologic status 14 months after cessation of natalizumab therapy

1 reference

12 December 2020

Progressive multifocal leukoencephalopathy complicating treatment with natalizumab and interferon beta-1a for multiple sclerosis

1 reference

12 December 2020

Demographic and clinic characteristics of French patients treated with natalizumab in clinical practice.

1 reference

12 December 2020

The effects of natalizumab on inflammatory mediators in multiple sclerosis: prospects for treatment-sensitive biomarkers.

1 reference

12 December 2020

Natalizumab reduces clinical and MRI activity in multiple sclerosis patients with high disease activity: results from a multicenter study in Switzerland.

1 reference

12 December 2020

Three years of experience: the Italian registry and safety data update.

1 reference

12 December 2020

Successful management of natalizumab-associated progressive multifocal leukoencephalopathy and immune reconstitution syndrome in a patient with multiple sclerosis

1 reference

12 December 2020

Effect of plasma exchange in accelerating natalizumab clearance and restoring leukocyte function

1 reference

12 December 2020

A randomized, placebo-controlled trial of natalizumab for relapsing multiple sclerosis

1 reference

12 December 2020

Swedish natalizumab (Tysabri) multiple sclerosis surveillance study

1 reference

12 December 2020

Anti-JC virus antibodies: implications for PML risk stratification

1 reference

12 December 2020

Anti-alpha4 integrin therapy for multiple sclerosis: mechanisms and rationale.

1 reference

12 December 2020

Natalizumab treatment in multiple sclerosis: the experience of S. Andrea MS Centre in Rome.

1 reference

12 December 2020

Progressive multifocal leukoencephalopathy in a patient treated with natalizumab

1 reference

12 December 2020

Treatment of progressive multifocal leukoencephalopathy associated with natalizumab.

1 reference

12 December 2020

Postwithdrawal rebound increase in T2 lesional activity in natalizumab-treated MS patients

1 reference

12 December 2020

Evidence Report: The efficacy and safety of mitoxantrone (Novantrone) in the treatment of multiple sclerosis: Report of the Therapeutics and Technology Assessment Subcommittee of the American Academy of Neurology

1 reference

12 December 2020

Efficacy and tolerability of natalizumab in relapsing-remitting multiple sclerosis patients: a post-marketing observational study

1 reference

12 December 2020

Safety and efficacy of natalizumab in children with multiple sclerosis

1 reference

12 December 2020

10.1007/S10072-010-0469-0

Identifiers

DOI

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21234775%20AND%20SRC:MED&resulttype=core&format=json

20 January 2020

1 reference